An announcement from Illumina ( (ILMN) ) is now available.
On March 10, 2025, Illumina announced an updated non-GAAP diluted EPS guidance for fiscal year 2025 and a cost reduction program. The company is addressing export restrictions imposed by China’s Ministry of Commerce, which could impact its revenue from the Greater China business. Despite these challenges, Illumina remains committed to expanding its multiomics portfolio and achieving high-single-digit revenue growth by 2027. The company expects a fiscal 2025 non-GAAP diluted EPS of approximately $4.50 and plans to implement a $100 million cost reduction program to mitigate potential revenue impacts from the Chinese market.
More about Illumina
Illumina is a global leader in DNA sequencing and array-based technologies, focusing on innovation to improve human health. The company serves customers in research, clinical, and applied markets, with products used in life sciences, oncology, reproductive health, agriculture, and emerging segments.
YTD Price Performance: -33.84%
Average Trading Volume: 2,575,816
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $13.72B
Find detailed analytics on ILMN stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com